Welcome to our dedicated page for TRINITY BIOTECH PLC SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trinity Biotech plc SEC filings document foreign-issuer reports furnished on Form 6-K for its diagnostics, diabetes management, and health technology operations. The filings record announcements tied to Premier Hb9210 diabetes testing, CGM+ biosensor development, EpiCapture prostate cancer diagnostics, North America commercial operations, trading updates, and the Comprehensive Transformation Plan.
The company’s filings also disclose ADS and ordinary-share capital matters, including a standby equity purchase agreement; credit-agreement waivers and covenant deferrals; Nasdaq listing-compliance notices for the ADSs; and incorporation by reference into Form S-8 registration statements. These records describe the formal reporting framework for Trinity Biotech as a foreign private issuer using Form 20-F reporting status.
Trinity Biotech plc files its annual Form 20-F for the year ended December 31, 2025, highlighting ongoing losses, high leverage and material risk factors. The company reported net losses of US$37.4 million in 2025 and US$31.8 million in 2024 and negative operating cash flows in both years.
Trinity carries total indebtedness of about US$141.3 million, including a senior secured Term Loan to Perceptive and a junior convertible note to MiCo, with US$108.0 million of variable‑rate debt accruing at roughly 12.75% annually. Management states that continuation as a going concern depends on generating operating cash and obtaining additional financing while executing a transformation plan focused on manufacturing consolidation, cost reduction and expansion into biosensor and continuous glucose monitoring products.
Trinity Biotech plc director Ronan O'Caoimh has filed an initial ownership report showing significant direct stakes in the company. He reports holding 486,208 ADS as of the filing date. In addition, he holds multiple ADS option awards with exercise prices of $13.70, $14.50, $3.80 and $2.80 per ADS, with expiration dates ranging from 2026 to 2031, providing potential future rights to acquire additional ADS over several years.
Trinity Biotech plc director John Gillard filed an amended initial insider report detailing his existing holdings in American Depositary Share (ADS) options and ADSs. The filing shows multiple option grants, including ADS options over 40,000 shares at an exercise price of $5.70 expiring on December 19, 2029, and ADS options over 43,750 shares at an exercise price of $2.40 expiring on December 11, 2030. It also notes ADS options over 7,500 shares at an exercise price of $13.45 expiring on October 23, 2027, along with direct ownership of 10,000 ADSs. The report records holdings only and does not show any new purchases or sales.
TRINITY BIOTECH PLC filed a Form 3 to report that Paul Murphy, the company’s Interim CFO, is now an insider required to report holdings and future trades in the company’s securities. The filing lists no initial share or option positions and shows no buy, sell, or exercise activity.
Trinity Biotech plc director John Paul Tivnan has filed a Form 3 insider ownership report for ticker TRIB. The data provided show no reported transactions, with buy, sell, exercise, gift, tax withholding, and restructuring share counts all at zero, indicating purely a baseline regulatory filing.
TRINITY BIOTECH PLC director John Gillard filed an initial statement of beneficial ownership, showing holdings of ADS options and common ADS. The filing lists multiple option grants over TRIB ADS with exercise prices between $2.40 and $13.45, plus 10,000 ADS held directly.
Trinity Biotech plc director Andrew Omidvar filed an initial Form 3 reporting holdings of ADS options. The options have an exercise price of $2.80 per ADS and expire on February 2, 2031. Multiple option tranches cover underlying ADS amounts of 7,292 and 2,917, with various future exercise dates extending into 2027.
Trinity Biotech plc announced successful clinical study results for an enhanced version of its EpiCapture™ prostate cancer test and outlined commercialization plans, while also obtaining a limited waiver under its Credit Agreement. The upgraded urine-based test now uses a machine learning algorithm that integrates DNA biomarkers with patient features such as ethnicity to improve individualized risk prediction for aggressive prostate cancer.
In an independently conducted study of approximately 750 patient samples, the next-generation EpiCapture™ achieved a clinical accuracy (AUC) of 85%, a level described as strong and clinically useful in oncology diagnostics. Trinity Biotech plans to launch EpiCapture™ in the U.S. as a proprietary Laboratory Developed Test through its New York reference laboratory, marking its first entry into precision oncology diagnostics. The company also disclosed that, under the limited waiver for covenant 8.15 with Perceptive Credit Holdings III, interest accruing in March 2026 will be capitalized and added to the principal balance of its debt.
Trinity Biotech plc filed a Form 6-K highlighting two growth initiatives in diabetes care. Senior executives are attending the ATTD 2026 conference in Barcelona to advance collaborations and commercialization plans for the next‑generation CGM+ continuous glucose monitoring platform, which is being prepared for a pivotal clinical trial in 2026.
The company has also begun commercial rollout in Brazil of its upgraded Premier Hb9210 HbA1c column system after local regulatory approval. The Premier Hb9210 platform is described as the only HbA1c system worldwide with IFCC “Gold” classification for 2026, and Trinity Biotech has strengthened its Brazilian commercial leadership with the appointment of Bruna Gigliotti.
Trinity Biotech plc is updating its Form F-1 prospectus to cover the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The ADSs trade on Nasdaq under the symbol TRIB and the last reported sale price on March 9, 2026 was $0.7010.
The supplement incorporates Form 6‑K materials filed March 10, 2026, including a press release describing technical breakthroughs for the company’s next‑generation CGM+ continuous glucose monitoring platform and a trading/business update that discloses a limited waiver and a covenant deferral under its Credit Agreement through July 1, 2026, and operational actions such as outsourcing Uni‑Gold™ HIV manufacturing.